Drugs / VLPM01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03867331 | Mar 2019 → May 2020 | Plasmodium falciparum malaria | VLP Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-02-04 | VLP Therapeutics | Regulatory VLP Therapeutics Receives FDA Clearance of Investigational New Drug Application and Initiates First Clinical Trial of VLPM01 Malaria Vaccine vlptherapeutics.com ↗
VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a clinical trial of the Company’s VLPM01 malaria vaccine. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-02-04 | VLP Therapeutics | VLP Therapeutics Receives FDA Clearance of Investigational New Drug Application and Initiates First Clinical Trial of VLPM01 Malaria Vaccine vlptherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VLPM01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03867331 ↗ |
| Modality | Vaccine | “VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine” NCT03867331 ↗ |
| Route | Intramuscular | “intramuscular administration” NCT03867331 ↗ |